Mary Klotman, MD, chair of the Department of Medicine, and Michael Kastan, MD, PhD, executive director of the Duke Cancer Institute, have announced that James Abbruzzese, MD, has agreed to be the Chief of the Division of Medical Oncology and Associate Director for Clinical Research for the Duke Cancer Institute effective Nov. 11, 2013.
Currently, Dr. Abbruzzese holds the Waun Ki Hong Distinguished Chair in Translational Oncology and he is chairman of the Department of Gastrointestinal Medical Oncology and Digestive Diseases at the University of Texas M. D. Anderson Cancer Center in Houston.
As associate director for clinical research in the DCI, Abbruzzese will guide and direct DCI’s 13 oncology disease-based clinical research groups, and he will be responsible for the clinical trials operation that encompasses more than 1,000 open trials with an average annual accrual of 6,000 patients. This is a role that has been held by Christopher Willett, MD, since the formation of the institute.
Abbruzzese also will lead the Division of Medical Oncology, a major partner in DCI. The Division has 58 full-time, regular-rank faculty members, and the clinical faculty now see more than 42,000 outpatients and 12,000 inpatients in more than 5,200 clinic sessions each year. Just as importantly, the Division has a major research mission with a current research portfolio of $76 million in funding, 111 grants – of which 36 are NIH funded – and 188 active clinical trials. Read more about James Abbruzzese.
By studying the mechanism of action behind cancer drugs and the mechanisms behind resistance to those drugs, researchers in the Duke Experimental Therapeutics Program are developing smarter therapies.
Visit DukeHealth.org for information about patient care services offered by Duke University Health System.